The Winthrop P. Rockefeller Cancer Institute is enrolling patients in its newly established Phase 1 Cancer Clinical Trials Unit. We’ve recently opened a novel clinical trial sponsored by Jounce Therapeutics, titled: “Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies.”
Led by Michael Birrer, M.D., Ph.D., Cancer Institute director, this study will bring a novel approach of harnessing the body’s immune system to treat cancer patients who have failed multiple lines of chemo and immunotherapies. The Cancer Institute is currently enrolling ovarian, breast, lung, and head and neck cancer patients to benefit future treatment options. Questions? mrkovak@uams.edu.